Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway

Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway

Sacubitril/valsartan (Sac/Val) is a recently approved drug that is commonly used for treatment of heart failure. Several studies indicated that Sac/Val also regulated the secretion of inflammatory factors. However, the effect and mechanism of this drug modulation of inflammatory immune responses are...

Full description

Bibliographic Details
Main Authors: Wei Liang, Bai-Kang Xie, Pei-Wu Ding, Min Wang, Jing Yuan, Xiang Cheng, Yu-Hua Liao, Miao Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Pharmacology
Subjects:
sacubitril/valsartan
Th17 cell differentiation
NLRP3 inflammasome
myocarditis
NF-κB p65
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.727838/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.727838/full

Similar Items